BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. BION is the largest biotech investor among its investment company peers. It invests in high-quality biotech assets that target substantial market opportunities. BION’s managers are optimistic about the outlook for the sector. They believe sentiment towards the sector should improve as interest rates peak and begin to decline. Meanwhile, they expect to see ongoing fundamental progress by portfolio holdings, with several due to reach key regulatory, clinical or commercial milestones over coming months. In addition, historically low valuations have created opportunities to add or top up exposure to interesting companies at attractive prices. BION differentiates itself from its peers by its highly competitive dividend policy – it pays a dividend equivalent to 5% of the average share price over December each year.